Bonnie Wu

Bonnie Wu

Auto-generated profile, based on publicly available information

Bonnie Wu

Johnson & Johnson Innovative Medicine, Spring House, PA, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2025 in The AAPS Journal
Verified
Journal Article
Open access
MPMichael A. Partridge
Michael A. Partridge
LKLynn Kamen
Lynn Kamen
BWBonnie Wu
Bonnie Wu
HSHelene Solberg
Helene Solberg
JMJim McNally
Jim McNally
JWJoleen White
Joleen White
Neutralizing antibodies (NAbs) to protein therapeutics have traditionally been assumed to be the most impactful subset of anti-drug-antibodies (ADA). NAbs can block the biotherapeutic from engaging its target impacting efficacy and may also cause serious safety events. Stand-alone NAb assays have been employed to detect neutralizing responses, often with reconfigured versions of other assays. These methods have historically been implemented in registrational trials for all molecules, and in early-stage studies for high risk biotherapeutics. However, data has demonstrated that NAb response and ADA magnitude are highly correlated. Additionally, the use of other markers to identify clinically relevant immunogenicity, such as apparent impact on pharmacokinetics (PK) or pharmacodynamics (PD), has been increasing. This manuscript reviews the available data on clinically meaningful immunogenic responses to biologics and proposes a risk-based strategy to determine if and when to employ a stand-alone NAb assay. For molecules with a high risk of safety consequences of immunogenicity (e.g., biological mimics) a NAb assay is recommended. However, for lower-safety risk molecules a stand-alone NAb assay does not enhance the interpretation of clinical data and is likely not needed. A combination of other assessments including ADA status, magnitude and persistence, PK, and PD (and efficacy) can be used as a surrogate for NAb assay data. Integration of data from all clinical evaluations is recommended by Health Authorities and can provide a more accurate overall assessment of neutralizing activity. This approach identifies clinically impactful downstream readouts of neutralizing activity without the need for a stand-alone NAb assay. Graphical Abstract

5 January 2026 in The AAPS Journal
Verified
Journal Article
Closed access
PDF file
BGBoris Gorovits
Boris Gorovits
MAMitra Azadeh
Mitra Azadeh
MFMichele Fiscella
Michele Fiscella
THTravis Harrison
Travis Harrison
MHMagdalena Hofer
Magdalena Hofer
AZAn Zhao
An Zhao


22 January 2026 in Bioanalysis
Verified
Journal Article
Closed access
PTPai-Chi Tsai
Pai-Chi Tsai
TCTara Condos
Tara Condos
JDJames Devlin
James Devlin
KCKrishna Chaitanya
Krishna Chaitanya
EPElisabeth Geyer Prinslow
Elisabeth Geyer Prinslow
YJYong Jiang
Yong Jiang
1. The evaluation of immunogenicity, the assessment of antidrug antibody (ADA) responses, is essential in biotherapeutic development [1,2]. The clinical implications of ADAs can vary significantly,...